Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript

28d ago, source: InvestingChannel on MSN

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024 Cellectar Biosciences, Inc. isn't ...

CLRB Cellectar Biosciences, Inc.

25d ago, source: Seeking Alpha

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug ...

Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why

1mon ago, source: Hosted on MSN

Monday, Cellectar Biosciences Inc (NASDAQ:CLRB) announced that iopofosine I 131 combined with external beam radiation therapy (EBRT) was safe and tolerated in a SPORE Grant-supported investigator ...

Cellectar Biosciences Inc Registered Shs hosts conference call for investors

29d ago, source: Business Insider

The company, Cellectar Biosciences Inc Registered Shs, is set to host investors and clients on a conference call on 3/27/2024 7:06:17 AM. The call comes after the company's earnings, which are set ...

Cellectar Biosciences, Inc.

19d ago, source: CNN

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse ...

Q4 2023 Cellectar Biosciences Inc Earnings Call

29d ago, source: Yahoo Finance

James Caruso; President, Chief Executive Officer, Director; Cellectar Biosciences Inc Andrei Shustov; Senior Vice President - Medical; Cellectar Biosciences Inc Jarrod Longcor; Chief Operating ...

Cellectar Biosciences Inc CLRB

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?

28d ago, source: Yahoo Finance

We feel now is a pretty good time to analyse Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) business as it appears the company may be on the cusp of a considerable accomplishment. Cellectar ...

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

29d ago, source: Seeking Alpha

Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today's call is being recorded. Before we begin, I would like to remind everyone that statements made during this cal ...

Cellectar Biosciences Inc (CLRB)

2d ago, source: Investing

Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Oil & Gas, Financials and Consumer Goods sectors led shares higher. At the ...

Cellectar Biosciences Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...